Immunogenicity and protection-inducing ability of recombinant Plasmodium vivax rhoptry-associated protein 2 in Aotus monkeys: A potential vaccine candidate

Vaccine

Volumn 27, Issue 21, 2009, Pages 2870-2876

  Rojas Caraballo, Jose ^a   Mongui, Alvaro ^a,b   Giraldo, Manuel A ^a,b   Delgado, Gabriela ^c   Granados, Diana ^c   Millan Cortes, Diana ^a,b   Martinez, Paola ^a,b   Rodriguez, Raul ^a,b   Patarroyo, Manuel A ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD DEL ROSARIO   (Colombia)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Immune response; Plasmodium vivax; Rhoptry associated protein; Vaccine candidate

Indexed keywords

ALUM HYDROXIDE; ANTIBODY; CLINDAMYCIN; CYTOKINE; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MALARIA VACCINE; PRIMAQUINE; PYRIMETHAMINE; QUININE SULFATE; RECOMBINANT PROTEIN PVRAP2 VACCINE; RECOMBINANT RHOPTRY ASSOCIATED PROTEIN 2 VACCINE; SULFADOXINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; AOTUS NANCYMAAE; ARTICLE; CELL VACUOLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; MONKEY; NONHUMAN; PARASITEMIA; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; AOTIDAE; DISEASE MODELS, ANIMAL; IMMUNOGENETIC PROCESSES; MALARIA VACCINES; PLASMODIUM VIVAX; PROTOZOAN PROTEINS;

EID: 64449088031     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.083     Document Type: Article

References (44)

1. Snow R.W., Guerra C.A., Noor A.M., Myint H.Y., and Hay S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434 March (7030) (2005) 214-217
2. Higgs E.S., and Sina B. Plasmodium vivax vaccine research: steps in the right direction. Am J Trop Med Hyg 73 November (5 Suppl.) (2005) 1-2
3. Sina B. Focus on Plasmodium vivax. Trends Parasitol 18 July (7) (2002) 287-289
4. Hay S.I., Guerra C.A., Tatem A.J., Noor A.M., and Snow R.W. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 4 June (6) (2004) 327-336
5. Hommel M., David P.H., and Oligino L.D. Surface alterations of erythrocytes in Plasmodium falciparum malaria. Antigenic variation, antigenic diversity, and the role of the spleen. J Exp Med 157 April (4) (1983) 1137-1148
6. McBride J.S., Walliker D., and Morgan G. Antigenic diversity in the human malaria parasite Plasmodium falciparum. Science (New York, NY) 217 July (4556) (1982) 254-257
7. Rotman H.L., Daly T.M., and Long C.A. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Exp Parasitol 91 January (1) (1999) 78-85
8. Perrin L.H., Ramirez E., Lambert P.H., and Miescher P.A. Inhibition of P. falciparum growth in human erythrocytes by monoclonal antibodies. Nature 289 January (5795) (1981) 301-303
9. Saul A., Cooper J., Hauquitz D., Irving D., Cheng Q., Stowers A., et al. The 42-kilodalton rhoptry-associated protein of Plasmodium falciparum. Mol Biochem Parasitol 50 January (1) (1992) 139-149
10. Lopez R., Valbuena J., Curtidor H., Puentes A., Rodriguez L.E., Garcia J., et al. Plasmodium falciparum: red blood cell binding studies using peptides derived from rhoptry-associated protein 2 (RAP2). Biochimie 86 January (1) (2004) 1-6
11. Stowers A., Taylor D., Prescott N., Cheng Q., Cooper J., and Saul A. Assessment of the humoral immune response against Plasmodium falciparum rhoptry-associated proteins 1 and 2. Infect Immun 65 June (6) (1997) 2329-2338
12. Collins W.E., Walduck A., Sullivan J.S., Andrews K., Stowers A., Morris C.L., et al. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys. Am J Trop Med Hyg 62 April (4) (2000) 466-479
13. Patarroyo M.A., Perez-Leal O., Lopez Y., Cortes J., Rojas-Caraballo J., Gomez A., et al. Identification and characterisation of the Plasmodium vivax rhoptry-associated protein 2. Biochem Biophys Res Commun 337 November (3) (2005) 853-859
14. Nardin E.H., and Nussenzweig R.S. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 11 (1993) 687-727
15. Perlmann P., and Troye-Blomberg M. Malaria and the immune system in humans. Chem Immunol 80 (2002) 229-242
16. Marsh K., and Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 28 January-February (1-2) (2006) 51-60
17. Wipasa J., Elliott S., Xu H., and Good M.F. Immunity to asexual blood stage malaria and vaccine approaches. Immunol Cell Biol 80 October (5) (2002) 401-414
18. Role of non-human primates in malaria vaccine development: memorandum from a WHO meeting. Bulletin of the World Health Organization 1988; 66(6):719-28.
19. Andrysiak P.M., Collins W.E., and Campbell G.H. Concentration of Plasmodium ovale- and Plasmodium vivax-infected erythrocytes from nonhuman primate blood using Percoll gradients. Am J Trop Med Hyg 35 March (2) (1986) 251-254
20. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. BioTechniques 15 September (3) (1993) 532-534 [6-7]
21. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 150 October (1) (1985) 76-85
22. Mann H.B., and Whitney D.R. On a test of wheter one of two random variables is stochastically larger than the other. Ann Math Stat 18 (1947) 50-60
23. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1 (1945) 80-83
24. Curtidor H., Ocampo M., Tovar D., Lopez R., Garcia J., Valbuena J., et al. Specific erythrocyte binding capacity and biological activity of Plasmodium falciparum-derived rhoptry-associated protein 1 peptides. Vaccine 22 February (8) (2004) 1054-1062
25. Sterkers Y., Scheidig C., da Rocha M., Lepolard C., Gysin J., and Scherf A. Members of the low-molecular-mass rhoptry protein complex of Plasmodium falciparum bind to the surface of normal erythrocytes. J Infect Dis 196 August (4) (2007) 617-621
26. Perrin L.H., Merkli B., Gabra M.S., Stocker J.W., Chizzolini C., and Richle R. Immunization with a Plasmodium falciparum merozoite surface antigen induces a partial immunity in monkeys. J Clin Invest 75 May (5) (1985) 1718-1721
27. Ridley R.G., Takacs B., Etlinger H., and Scaife J.G. A rhoptry antigen of Plasmodium falciparum is protective in Saimiri monkeys. Parasitology 101 October (Pt 2) (1990) 187-192
28. Brewer J.M., and Alexander J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines Cell Mol Ther 3 December (4) (1997) 233-246
29. Grun J.L., and Maurer P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 121 June (1) (1989) 134-145
30. Cox J.C., and Coulter A.R. Adjuvants-a classification and review of their modes of action. Vaccine 15 February (3) (1997) 248-256
31. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr Opinion Immunol 12 August (4) (2000) 456-463
32. Brewer J.M., and Pollock K.G. Adjuvant-Induced Th2- and Th1-Dominated Immune Responses in Vaccination. In: Kaufmann S.H. (Ed). Novel Vaccination Strategies (2004), Wiley-VCH Verlag GmbH & Co, Berlin 51-72
33. Freund J., Casals J., and Hosmaer E.P. Sensitisation and antibody formation after injection of tuberculi bacilli and paraffin oil. Proc Soc Exp Biol Med 37 (1937) 509-513
34. Yip H.C., Karulin A.Y., Tary-Lehmann M., Hesse M.D., Radeke H., Heeger P.S., et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 162 April (7) (1999) 3942-3949
35. Kocken C.H., Dubbeld M.A., Van Der Wel A., Pronk J.T., Waters A.P., Langermans J.A., et al. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect Immun 67 January (1) (1999) 43-49
36. Baum J., Thomas A.W., and Conway D.J. Evidence for diversifying selection on erythrocyte-binding antigens of Plasmodium falciparum and P. vivax. Genetics 163 April (4) (2003) 1327-1336
37. Cole-Tobian J., and King C.L. Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol Biochem Parasitol 127 April (2) (2003) 121-132
38. Oliveira-Ferreira J., Vargas-Serrato E., Barnwell J.W., Moreno A., and Galinski M.R. Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli. Vaccine 22 May (15-16) (2004) 2023-2030
39. Rodrigues M.H., Rodrigues K.M., Oliveira T.R., Comodo A.N., Rodrigues M.M., Kocken C.H., et al. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int J Parasitol 35 February (2) (2005) 185-192
40. Espinosa A.M., Sierra A.Y., Barrero C.A., Cepeda L.A., Cantor E.M., Lombo T.B., et al. Expression, polymorphism analysis, reticulocyte binding and serological reactivity of two Plasmodium vivax MSP-1 protein recombinant fragments. Vaccine 21 March (11-12) (2003) 1033-1043
41. Barrero C.A., Delgado G., Sierra A.Y., Silva Y., Parra-Lopez C., and Patarroyo M.A. Gamma interferon levels and antibody production induced by two PvMSP-1 recombinant polypeptides are associated with protective immunity against P. vivax in Aotus monkeys. Vaccine 23 July (31) (2005) 4048-4053
42. Sierra A.Y., Barrero C.A., Rodriguez R., Silva Y., Moncada C., Vanegas M., et al. Splenectomised and spleen intact Aotus monkeys' immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. Vaccine 21 October (27-30) (2003) 4133-4144
43. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., and Gupta C.K. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 11 3 (1993) 293-306
44. Ishii K.J., and Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 27 July (4) (2007) 363-371